Dis, Thank you for your criticism. Quote: "A restricted Relenza supply benefits the sale of GSK Pandamic Flu Vaccines. This is reflected in the disproportionate sale of Relenza to GSK Vaccines and Roche's performance." This a Rubbish with a capital R. You use a (flu) vaccine to prevent flu and you use an antiviral to treat a person with flu IF THEY REQUIRE TREATMENT - the vast majority do not. Are you seriously suggesting that GSK will with hold Relenza supply so that there will be 1000's of extra deaths; and they will use this post mortem analysis to promote their vaccine for future years. Get real!
You obviously new to BTA forum and have not read earlier postings. I hope I am able to assist you by repeating the earlier post:
Buyer: Mr Witty, my government want to place 10 million courses of Relenza.
Mr Witty: No problem. Let me look at my production schedule. Yes, we will deliver the first 3 million in July 2010 and the remainder in September.
Buyer: Hello, are you for real? By then my people will be dead and the pandemic may be over!
Mr Witty: No they wont be dead. You can buy 30 million doses of our Pandemic Vaccines for the same amount of money that you could only buy 10 million of Relenza.
Buyer: You are a genius. They don’t call you Witty for no reason!
Dis, obviously the above is a fictional conversation that could be taking place right now. I hope it is simple enough for you.
BTA Price at posting:
$1.88 Sentiment: None Disclosure: Not Held
